Lokelma allows higher heart med doses in kidney patients
NCT ID NCT05004363
First seen Apr 30, 2026 · Last updated May 20, 2026 · Updated 3 times
Summary
This study tested whether a drug called Lokelma (SZC) can help people with both heart failure and chronic kidney disease safely take higher doses of standard heart medications (RAAS inhibitors) without dangerous potassium spikes. 112 adults with stable kidney disease and high-normal potassium levels were randomly given Lokelma or a placebo while their heart medication doses were increased. The goal was to see if Lokelma allowed more patients to reach the maximum recommended heart medication dose while keeping potassium levels safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
St Georges, University of London
London, United Kingdom
Conditions
Explore the condition pages connected to this study.